Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy

Am J Hematol. 2024 Jul;99(7):1423-1426. doi: 10.1002/ajh.27329. Epub 2024 Apr 12.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Female
  • Humans
  • Imidazoles* / administration & dosage
  • Imidazoles* / adverse effects
  • Imidazoles* / therapeutic use
  • Male
  • Middle Aged
  • Philadelphia Chromosome*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridazines* / administration & dosage
  • Pyridazines* / adverse effects
  • Pyridazines* / therapeutic use
  • Recurrence*

Substances

  • ponatinib
  • Pyridazines
  • Imidazoles
  • Antineoplastic Agents
  • Protein Kinase Inhibitors